Onyx retains Nexavar/regorafenib rights on takeover as Bayer settles dispute
This article was originally published in Scrip
Onyx Pharmaceuticals has settled ongoing litigation with partner Bayer in which Onyx claimed it has rights to Bayer's Phase III investigational targeted anticancer, regorafenib (BAY 73-4506). The two parties have agreed that Onyx will be entitled to a cut of future sales (20% royalty on worldwide sales), if the product gains approval, and certain other rights. The candidate has been dubbed fluoro-sorafenib, since it is a variant of the partners' currently marketed Nexavar (sorafenib), which the two market jointly worldwide.